DIRECTIONS

THE NATIONAL HEALTH SERVICE ACT 2006

The Pharmaceutical Services (Advanced and Enhanced Services) (England) (Amendment) (No. 2) Directions 2014

The Secretary of State gives the following Directions in exercise of the powers conferred by sections 127, 128, 272(7) and (8) and 273(1) of the National Health Service Act 2006(a).

Citation, commencement, application and interpretation

- 1.—(1) These Directions may be cited as the Pharmaceutical Services (Advanced and Enhanced Services) (England) (Amendment) (No. 2) Directions 2014.
 - (2) These Directions-
 - (a) apart from direction 2, come into force on 1st January 2015; and
 - (b) direction 2 comes into force on 1st April 2015.
 - (3) These Directions apply in relation to England.
- (4) In these Directions, "the 2013 Directions" means the Pharmaceutical Services (Advanced and Enhanced Services) (England) Directions 2013(b).

Amendment of direction 5 of the 2013 Directions

2. In direction 5(1) of the 2013 Directions (MUR services: ongoing conditions of arrangements), in sub-paragraph (g), for "50%" substitute "70%".

Amendment of direction 14 of the 2013 Directions

- 3. In direction 14(1) of the 2013 Directions (enhanced services provided by pharmacy contractors), after sub-paragraph (a) insert the following sub-paragraph—
 - "(aa) an Antiviral Collection Service, the underlying purpose of which is for P to supply antiviral medicines, in accordance with regulation 247 of the Human Medicines Regulations 2012(c) (exemption for supply in the event or in anticipation of pandemic disease), to patients for treatment or prophylaxis;".

Amendment of Schedule 1 to the 2013 Directions

4. In Schedule 1 to the 2013 Directions (national target groups for MUR services), after paragraph 3 insert the following paragraph—

(a) 2006 c. 41. Section 127 has been amended by the Health and Social Care Act 2012 (c. 7) ("the 2012 Act"), Schedule 4, paragraph 64; and section 128 has been amended by the 2012 Act, Schedule 4, paragraph 65.
(b) Signed on 12th March 2013, and amended by: the Pharmaceutical Services (Advanced and Enhanced Services) (England)

(c) Amended by S.I. 2013/235.

⁽b) Signed on 12th March 2013, and amended by: the Pharmaceutical Services (Advanced and Enhanced Services) (England) (Amendment) Directions 2013, signed on 16th September 2013; and the Pharmaceutical Services (Advanced and Enhanced Services) (England) (Amendment) (No. 2) Directions 2013, signed on 6th December 2013, which also revoked the Pharmaceutical Services (Advanced and Enhanced Services) (England) (Amendment) Directions 2013; and the Pharmaceutical Services (Advanced and Enhanced Services) (England) (Amendment) Directions 2014, signed on 12th March 2014.

"4. Patients who are regularly being prescribed four or more medicines, at least one of which is a medicine which is included in the BNF chapter and subsections referenced in the table in this paragraph—

RNF Reference	KNF subsection descriptor
Chapter 2	Cardiovascular System
Sub Chapter 6.1	Drugs used in Diabetes
Sub Chapter 6.2	Thyroid and Anti Thyroid Drugs

Signed by authority of the Secretary of State for Health

TAHowe

5th December 2014

Jeannette Howe Head of Pharmacy Department of Health